Bayer: positive results for an MRI contrast agent

(CercleFinance.com) - Bayer announces positive results from a Phase III study evaluating the efficacy and safety of gadoquatrane, a gadolinium-based contrast agent for MRI.


With a reduced gadolinium dose (0.04 mmol Gd/kg, or 60% less than standard doses), gadoquatrane met both primary and secondary endpoints in studies involving the central nervous system, other body regions and pediatric patients.

The observed safety profile is consistent with previous data, with no new signals. Bayer plans to submit these results to the health authorities for marketing authorisation.


Copyright (c) 2025 CercleFinance.com. All rights reserved.